Skip to main content

Alnylam Presents Data on AAT Drug


Alnylam Pharmaceuticals this week presented preclinical data on its investigational treatment for alpha-1 antitrypsin deficiency-associated liver disorders.

AAT is a liver-produced serine proteinase inhibitor that protects the lungs from neutrophil elastase and other irritants that cause inflammation, according to Alnylam. In the liver, misfolding of the mutant form of the protein disrupts its normal release into the blood, causing it to aggregate in hepatocytes. The result can be liver injury, fibrosis, cirrhosis, and liver cancer.

Alnylam's drug, called ALN-AAT, is designed to inhibit AAT. In a mouse model triggered rapid, potent, dose-dependent, and durable knockdown of its target of greater than 90 percent, Alnylam said. A significant reduction in fibrosis and the incidence of liver tumors was also observed.

Alnylam, which presented these data at the annual meeting of the American Association for the Study of Liver Diseases, has previously said that it will only advance ALN-AAT into human testing with a partner.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.